CRIS Current Research Information System

DI MARCO, MARIACRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.613
AS - Asia 8.340
EU - Europa 6.191
AF - Africa 643
SA - Sud America 438
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 24.243
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.504
VN - Vietnam 2.306
CN - Cina 2.192
SG - Singapore 2.134
IT - Italia 1.352
GB - Regno Unito 1.226
SE - Svezia 750
DE - Germania 724
HK - Hong Kong 560
FR - Francia 394
IN - India 374
BR - Brasile 305
RU - Federazione Russa 281
CH - Svizzera 277
IE - Irlanda 247
NL - Olanda 224
UA - Ucraina 210
KR - Corea 168
CI - Costa d'Avorio 153
FI - Finlandia 141
ZA - Sudafrica 140
TG - Togo 129
JP - Giappone 128
EE - Estonia 86
NG - Nigeria 83
SC - Seychelles 82
AT - Austria 68
PH - Filippine 65
CA - Canada 60
JO - Giordania 58
BD - Bangladesh 53
BG - Bulgaria 53
AR - Argentina 44
TH - Thailandia 42
ID - Indonesia 41
BE - Belgio 37
TR - Turchia 30
IQ - Iraq 28
EC - Ecuador 25
MX - Messico 25
ES - Italia 24
PK - Pakistan 23
CL - Cile 22
PL - Polonia 22
TW - Taiwan 22
IR - Iran 16
UZ - Uzbekistan 15
SA - Arabia Saudita 13
GR - Grecia 12
LB - Libano 12
CO - Colombia 11
HR - Croazia 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
DZ - Algeria 10
LT - Lituania 10
MY - Malesia 10
EG - Egitto 9
NP - Nepal 9
PY - Paraguay 8
VE - Venezuela 8
NI - Nicaragua 7
PE - Perù 7
PT - Portogallo 7
CZ - Repubblica Ceca 6
JM - Giamaica 6
PS - Palestinian Territory 6
MA - Marocco 5
RO - Romania 5
TN - Tunisia 5
UY - Uruguay 5
AZ - Azerbaigian 4
CR - Costa Rica 4
ET - Etiopia 4
HU - Ungheria 4
KE - Kenya 4
KZ - Kazakistan 4
RS - Serbia 4
SN - Senegal 4
BO - Bolivia 3
DK - Danimarca 3
EU - Europa 3
MU - Mauritius 3
OM - Oman 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BY - Bielorussia 2
CM - Camerun 2
DO - Repubblica Dominicana 2
IL - Israele 2
ME - Montenegro 2
MM - Myanmar 2
MT - Malta 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AO - Angola 1
AQ - Antartide 1
BT - Bhutan 1
BW - Botswana 1
Totale 24.220
Salva come PNG Salva come JPEG
Città #
Singapore 1.467
Southend 1.055
Ashburn 943
Chandler 694
Fairfield 682
Hong Kong 516
Ho Chi Minh City 511
Hanoi 454
San Jose 437
Dallas 336
Santa Clara 329
Houston 325
Hefei 317
Princeton 285
Woodbridge 275
Beijing 272
Bern 266
Bologna 261
Wilmington 261
Dong Ket 256
Dublin 247
Seattle 245
Ann Arbor 231
Cambridge 211
New York 185
Los Angeles 171
Boardman 164
Abidjan 153
Lauterbourg 152
Seoul 134
Lomé 129
Helsinki 118
Nanjing 112
Jacksonville 110
Westminster 109
Tokyo 101
Padova 98
Council Bluffs 96
Milan 86
Berlin 82
Da Nang 78
Turin 76
Haiphong 74
Jinan 71
Frankfurt am Main 70
Shenyang 67
Abeokuta 65
Medford 65
Rome 63
Florence 60
Buffalo 58
Redondo Beach 58
Amman 55
Shanghai 55
Tianjin 54
Sofia 53
Guangzhou 52
Redmond 51
Munich 46
San Diego 46
Saint Petersburg 45
Hebei 40
Changsha 38
Nanchang 37
São Paulo 36
Hangzhou 35
Johannesburg 34
Vienna 34
Brussels 32
Dearborn 32
Des Moines 31
Mülheim 30
Nuremberg 30
Bengaluru 29
Falkenstein 29
Falls Church 29
Hải Dương 27
London 26
Tongling 26
Biên Hòa 25
Orem 25
Amsterdam 24
Bremen 24
Brooklyn 24
Zhengzhou 24
Jiaxing 23
Bến Tre 22
Can Tho 22
Jakarta 22
Phoenix 22
Chicago 21
Taiyuan 21
Toronto 21
Atlanta 20
Redwood City 20
Yubileyny 20
Bühl 18
San Francisco 18
Shenzhen 18
Düsseldorf 17
Totale 15.164
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 455
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 302
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 281
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 268
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 259
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: a single center prospective, randomized controlled study. 258
Higher number of known pancreatic cancer mutations highlighted by whole-transcripto- me and whole-exome sequencing predicts cli- nical outcome in early stage patients 254
Adjuvant chemoradiation in pancreatic cancer: Impact of radiotherapy dose on survival 250
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 248
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 247
β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer 241
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 240
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 235
Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis. 232
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 231
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 227
Comparing recist and Choi’s criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer 224
The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study 221
Mutational burden of resectable pancreatic cancer by whole-transcriptome and whole-exome sequencing could predict a poor prognosis 220
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 219
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 218
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 217
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 216
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 216
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre 215
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 213
Intraductal papillary mucinous neoplasms: the bologna experience. Lessons learned from 357 cases observed in a tertiary care center 212
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 209
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 202
Intraductal Papillary Mucinous Neoplasms: The Bologna Experience 202
Multicolour versus monocolour inking specimens after pancreaticoduodenectomy for periampullary cancer: A single centre prospective randomised clinical trial 201
Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression 199
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 199
Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case‐control study (PAULA‐1) 197
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 193
In Reply 191
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 191
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 191
Discovery of new potentially actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 189
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 189
Branch duct intraductal papillary mucinous neoplasm: validation of Fukuoka 2012 guidelines using a systematic review and meta-analysis 186
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 186
GemOx and Ovarian Pancreatic Cancer Metastasis (PC) 185
Discovery of new potential actionable mutations in pancreatic ductal adenocarcinoma by next generation sequencing 185
Treatment of colorectal cancer liver metastases 183
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study 183
Clinical impact of nonselective beta-blockers on survival in patients with pancreatic cancer- revival of well known drugs? 183
Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses 182
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 179
State of the art biological therapies in pancreatic cancer 178
Pancreatic ductal adenocarcinoma associated with autoimmune pancreatitis. 178
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 178
Comparing RECIST and Choi's Criteria After Neoadjuvant Chemoradiotherapy in Patients with Resectable Pancreatic Cancer 177
Prospective validation of a preoperative risk score model based on pancreatic texture to predict postoperative pancreatic fistula after pancreaticoduodenectomy. 176
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 175
Capecitabine(CAP) based regimens vs infusional 5FU/AF in metastatic colorectal cancer cost/effectivness: the differences across the atlantic ocean 174
Advanced pancreatic cancer (APC) A monocenter experience in 53 patients: is it possible a second line treatment? 173
Pancreatic cyst surveillance imposes low psychological burden 173
Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: A retrospective multicentre study 172
Risk Factors in Resected Pancreatic Cancer. A Single Centre Experience 171
Intraductal papillary mucinous neoplasms: the Bologna experience. Lessons learned from 357 cases observed in a tertiary care center 171
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib 170
The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study 170
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 168
Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets 168
Immunonutrition in patients who underwent major abdominal surgery: A comprehensive systematic review and component network metanalysis using GRADE and CINeMA approaches 167
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 167
External validation of nomogram for predicting malignant intraductal papillary mucinous neoplasm (IPMN): from the theory to the clinical practice using the decision curve analysis model 166
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 164
Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1) 164
Gemox in combination witherlotinib (E) in pancreatic cancer (PC). 159
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 159
Hacking pancreatic cancer: Present and future of personalized medicine 159
Advanced pancreatic cancer (apc); a Monocenter experience in 53 patients. It is possible a second line treatment? 158
Preoperatory Gemcitabine and Oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma 156
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI) 154
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice—a fifteen-year journey at a tertiary referral centre 154
Intervento educativo rivolto a giovani fumatori della scuola secondaria di secondo grado 154
The follow-up issues: from the necessity to the opportunity 154
Risk Factors for Malignancy of Branch-Duct Intraductal Papillary Mucinous Neoplasms: A Critical Evaluation of the Fukuoka Guidelines With a Systematic Review and Meta-analysis 154
CIRCULATING METALLOPROTEINASE-3 AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 IN PATIENTS WITH DUCTAL PANCREATIC NEOPLASMS 153
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOINSTITUTIONAL EXPERIENCE 152
EXOCRINE-ENDOCRINE PANCREATIC CANCER AND alpha-FETOPROTEIN 152
Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results - a single‑center experience 152
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 152
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? 151
Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. 151
Erratum: β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer (Cancer Cell (2018) 33(1) (75–90.e7), (S153561081730510X) (10.1016/j.ccell.2017.11.007)) 148
Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients. 147
Prognostic factors for recurrence in resected pancreatic adenocarcinoma: a single center experience 147
Whole-transcriptome paired-end sequencing and the pancreatic cancer genetic landscape 147
Whole Transcriptome Sequencing Reveals Molecular Prognostic Markers in Pancreatic Adenocarcinoma 146
Effect of the serine proteases inhibitor gabexate mesylate (GM) on the activity of gemcitabine (G) in cell lines of pancreatic cancer (PC) 146
Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1) 144
Hedgehog Signaling: from the Cuirass to the Heart of Pancreatic Cancer 144
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? 144
Locally Advanced Pancreatic Cancer: Is There a Role for Neoadjuvant Chemo-Radiation? A Case Report and Literature Review 143
Massively Parallel Sequencing Analysis of Genetic Alterations Carried by Pancreatic Adenocarcinoma 143
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 142
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma. 141
Totale 18.930
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.104
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.104
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021687 0 0 0 0 0 0 0 0 0 0 107 580
2021/20222.699 194 106 96 201 228 125 66 179 151 264 651 438
2022/20233.334 302 476 178 370 227 254 51 192 499 127 305 353
2023/20241.039 88 130 84 95 81 270 50 62 25 69 52 33
2024/20253.438 172 429 275 240 474 167 273 192 53 333 173 657
2025/20268.860 716 731 870 624 873 466 1.340 323 1.903 752 262 0
Totale 24.787